Send to

Choose Destination
Korean J Physiol Pharmacol. 2010 Feb;14(1):11-4. doi: 10.4196/kjpp.2010.14.1.11. Epub 2010 Feb 28.

Dendritic Cells-based Vaccine and Immune Monitoring for Hepatocellular Carcinoma.

Author information

Department of Pharmacology, Kosin University College of Medicine, Busan 602-703, Korea.


Human tumors, including those of the hepatobiliary system, express a number of specific antigens that can be recognized by T cells, and may provide potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare leucocytes that are uniquely potent in their ability to capture, process and present antigens to T cells. The ability to culture sufficient numbers of DCs from human bone marrow or blood progenitors has attracted a great deal of interest in their potential utilization in human tumor vaccination. CD34(+) peripheral blood stem cells (PBSCs) were obtained from a patient with a hepatocellular carcinoma. The PBSCs were cultured in the X-VIVO 20 medium supplemented with the Flt-3 Ligand (FL), GM-CSF, IL-4 and TNF-alpha for 12 days. The morphology and functions of the cells were examined. The generated cells had the typical morphology of DCs. When the DCs were reinjected into the same patient, an augmentation of the cytotoxic T lymphocyte (CTL) activity was observed. Concomitantly, an increase in the natural killer (NK) cell activity was also detected in the patient. These results suggest that DCs-based cancer immunotherapy may become an important treatment option for cancer patients in the future.


Cancer immunotherapy; Dendritic cells (DCs); Hepatocellular carcinoma; Natural killer (NK) cells; Peripheral blood stem cells (PBSCs)

Supplemental Content

Full text links

Icon for The Korean Physiological Society and The Korean Society of Pharmacology Icon for PubMed Central
Loading ...
Support Center